S&P 500   4,687.92 (+0.02%)
DOW   35,647.35 (-0.20%)
QQQ   397.96 (+0.03%)
AAPL   174.32 (+1.83%)
MSFT   331.55 (-1.01%)
FB   331.49 (+2.69%)
GOOGL   2,945.85 (+0.02%)
AMZN   3,518.61 (-0.13%)
TSLA   1,055.25 (+0.33%)
NVDA   317.73 (-2.02%)
BABA   126.73 (+0.95%)
NIO   34.82 (+5.13%)
CGC   11.11 (+4.42%)
AMD   144.61 (-0.17%)
GE   98.78 (+1.26%)
MU   85.54 (-0.34%)
T   23.10 (+0.09%)
F   19.91 (-0.25%)
DIS   153.28 (+1.64%)
PFE   51.38 (-0.66%)
AMC   33.21 (+6.99%)
ACB   6.68 (+4.70%)
BA   212.24 (+1.63%)
S&P 500   4,687.92 (+0.02%)
DOW   35,647.35 (-0.20%)
QQQ   397.96 (+0.03%)
AAPL   174.32 (+1.83%)
MSFT   331.55 (-1.01%)
FB   331.49 (+2.69%)
GOOGL   2,945.85 (+0.02%)
AMZN   3,518.61 (-0.13%)
TSLA   1,055.25 (+0.33%)
NVDA   317.73 (-2.02%)
BABA   126.73 (+0.95%)
NIO   34.82 (+5.13%)
CGC   11.11 (+4.42%)
AMD   144.61 (-0.17%)
GE   98.78 (+1.26%)
MU   85.54 (-0.34%)
T   23.10 (+0.09%)
F   19.91 (-0.25%)
DIS   153.28 (+1.64%)
PFE   51.38 (-0.66%)
AMC   33.21 (+6.99%)
ACB   6.68 (+4.70%)
BA   212.24 (+1.63%)
S&P 500   4,687.92 (+0.02%)
DOW   35,647.35 (-0.20%)
QQQ   397.96 (+0.03%)
AAPL   174.32 (+1.83%)
MSFT   331.55 (-1.01%)
FB   331.49 (+2.69%)
GOOGL   2,945.85 (+0.02%)
AMZN   3,518.61 (-0.13%)
TSLA   1,055.25 (+0.33%)
NVDA   317.73 (-2.02%)
BABA   126.73 (+0.95%)
NIO   34.82 (+5.13%)
CGC   11.11 (+4.42%)
AMD   144.61 (-0.17%)
GE   98.78 (+1.26%)
MU   85.54 (-0.34%)
T   23.10 (+0.09%)
F   19.91 (-0.25%)
DIS   153.28 (+1.64%)
PFE   51.38 (-0.66%)
AMC   33.21 (+6.99%)
ACB   6.68 (+4.70%)
BA   212.24 (+1.63%)
S&P 500   4,687.92 (+0.02%)
DOW   35,647.35 (-0.20%)
QQQ   397.96 (+0.03%)
AAPL   174.32 (+1.83%)
MSFT   331.55 (-1.01%)
FB   331.49 (+2.69%)
GOOGL   2,945.85 (+0.02%)
AMZN   3,518.61 (-0.13%)
TSLA   1,055.25 (+0.33%)
NVDA   317.73 (-2.02%)
BABA   126.73 (+0.95%)
NIO   34.82 (+5.13%)
CGC   11.11 (+4.42%)
AMD   144.61 (-0.17%)
GE   98.78 (+1.26%)
MU   85.54 (-0.34%)
T   23.10 (+0.09%)
F   19.91 (-0.25%)
DIS   153.28 (+1.64%)
PFE   51.38 (-0.66%)
AMC   33.21 (+6.99%)
ACB   6.68 (+4.70%)
BA   212.24 (+1.63%)

Biotechnology Stocks

Biotech companies leverage cutting-edge science to create medicines and treatments for a multitude of diseases, making them high-risk, high-reward opportunities for investors looking to profit from healthcare innovation. What is a biotech stock?

MarketRank evaluates a company based on community opinion, dividend strength, institutional and insider ownership, earnings and valuation, and analysts forecasts.
Available with a MarketBeat All Access Subscription
MarketRank™Upgrade to All Access to use the All Ranks Filter
Media sentiment refers to the percentage of positive news stories versus negative news stories a company has received in the past week.
Available with a MarketBeat All Access Subscription
Media SentimentUpgrade to All Access to use the All Sentiments Filter
Analyst consensus is the average investment recommendation among Wall Street research analysts.
Available with a MarketBeat All Access Subscription
Analyst ConsensusUpgrade to All Access to use the All Ratings Filter
CompanyCurrent PricePE RatioMarket CapVolumeAverage VolumeIndicator(s)
21.95$120.04 billion87,9792.65 millionDividend Increase
Analyst Report
8.38$70.50 billion100,2693.19 millionAnalyst Report
Gap Down
Regeneron Pharmaceuticals
10.27$69.18 billion8,523845,499Analyst Report
Vertex Pharmaceuticals
24.80$52.53 billion28,9051.99 millionAnalyst Revision
40.00$32.77 billion64,3974.44 million
N/A$27.06 billion10,032913,376
Genmab A/S
56.96$26.20 billion26,773482,199Gap Up
Royalty Pharma
30.50$23.89 billion26,2902.47 millionPositive News
Bio-Rad Laboratories
3.40$22.44 billion58138News Coverage
110.93$18.87 billion3,681250,539Analyst Downgrade
Charles River Laboratories International
47.61$18.59 billion4,482414,452Positive News
Healthpeak Properties
29.97$18.58 billion54,8233.17 millionAnalyst Report
10x Genomics
N/A$17.04 billion21,227745,500
47.28$16.61 billion2.30 million1.91 millionNews Coverage
N/A$15.53 billion2,527178,039Analyst Report
News Coverage
Ginkgo Bioworks
N/A$15.43 billion163,1535.45 million
ICON Public
70.25$14.59 billion5,111634,094
iShares Nasdaq Biotechnology ETF
N/A$9.80 billion122,1732.91 million
United Therapeutics
19.50$8.67 billion4,647367,310
Brooks Automation
73.83$8.18 billion7,192774,656News Coverage
44.00$7.65 billion1,788182,804
Legend Biotech
N/A$7.35 billion6,020450,685News Coverage
Stevanato Group
N/A$7.19 billion3,099575,710
17.43$6.64 billion7,7441.15 millionGap Down
Vir Biotechnology
N/A$5.49 billion17,5081.22 millionAnalyst Report
News Coverage
Beam Therapeutics
N/A$5.44 billion8,959839,503
Halozyme Therapeutics
11.83$4.65 billion18,2141.01 million
Adaptive Biotechnologies
N/A$4.11 billion15,410791,690
SpringWorks Therapeutics
N/A$3.53 billion11,632298,612Gap Up
Sana Biotechnology
N/A$3.48 billion7,696645,895
Recursion Pharmaceuticals
N/A$3.37 billion86,991697,457Analyst Report
News Coverage
N/A$3.37 billion5,606280,971
Amicus Therapeutics
N/A$3.19 billion48,7562.86 million
Arcus Biosciences
N/A$3.15 billion14,498580,193
Olink Holding AB (publ)
N/A$2.41 billion6,005261,340Gap Down
BioCryst Pharmaceuticals
N/A$2.19 billion42,6374.22 million
Myriad Genetics
N/A$2.10 billion5,953597,122Gap Down
Avid Bioservices
363.67$1.78 billion37,077725,532Earnings Report
Analyst Report
News Coverage
Gap Down
IGM Biosciences
N/A$1.72 billion2,299172,189News Coverage
Gap Down
Krystal Biotech
N/A$1.70 billion17,356197,438
N/A$1.64 billion14,280493,487
Rocket Pharmaceuticals
N/A$1.63 billion2,898430,798News Coverage
Gap Down
N/A$1.60 billion3,839174,045
Enanta Pharmaceuticals
N/A$1.54 billion1,987156,821
ADC Therapeutics
N/A$1.47 billion2,887268,656
Burning Rock Biotech
N/A$1.42 billion7,435355,742Gap Up
N/A$1.40 billion4,628408,576
N/A$1.38 billion60375,096
Replimune Group
N/A$1.37 billion3,064307,834
Standex International
30.45$1.29 billion21654,819Positive News
Sangamo Therapeutics
N/A$1.27 billion24,7781.18 million
Revance Therapeutics
N/A$1.20 billion9,588658,640Insider Buying
N/A$1.15 billion1,384255,013Gap Down
Tekla Healthcare Investors
N/A$1.07 billion4,791133,259
N/A$1.07 billion6,295360,020Quiet Period Expiration
N/A$1.04 billion6,555599,809Analyst Report
News Coverage
Gap Down
Tango Therapeutics
N/A$974.39 million1,51799,387
Zealand Pharma A/S
N/A$927.99 million18,04716,553Gap Up
Tenaya Therapeutics
N/A$892.08 million607172,295Gap Up
Heron Therapeutics
N/A$869.51 million85,1001.42 million
111.25$856.87 million571299,742
N/A$849.69 million24,1141.34 millionAnalyst Upgrade
Century Therapeutics
N/A$846.39 million3,479175,593News Coverage
Gritstone bio
N/A$828.77 million15,6461.53 million
N/A$813.21 million62,37211.48 millionAnalyst Revision
Aclaris Therapeutics
N/A$813.10 million6,0451.20 million
908 Devices
N/A$775.90 million8,290282,949Gap Down
Stoke Therapeutics
N/A$754.95 million2,176161,848
Silence Therapeutics
N/A$741.02 million20016,915
Dyne Therapeutics
N/A$714.69 million2,244290,870News Coverage
Gap Up
Omega Therapeutics
N/A$709.46 million97399,257
bluebird bio
N/A$694.06 million17,8861.63 millionAnalyst Upgrade
Diversified Healthcare Trust
N/A$685.92 million11,4931.24 million
Tutor Perini
6.99$682.32 million1,725312,913
Nautilus Biotechnology
N/A$651.88 million17,182469,447
Eagle Pharmaceuticals
113.98$603.47 million394108,100
Enochian Biosciences
N/A$600.01 million5,298775,157
VanEck Vectors Biotech ETF
N/A$566.94 million20015,036
Aligos Therapeutics
N/A$560.31 million3,301161,276News Coverage
Precision BioSciences
N/A$549.33 million8,330654,133
Vera Therapeutics
N/A$517.70 million3,61154,135Analyst Revision
Athira Pharma
N/A$514.70 million3,501627,937
Gracell Biotechnologies
N/A$479.92 million7,863229,569
Evelo Biosciences
N/A$477.40 million2,075259,783News Coverage
Adicet Bio
N/A$474.85 million98,761359,474Analyst Report
News Coverage
Invesco S&P SmallCap Health Care ETF
N/A$470.47 million6,8609,103
Tekla Life Sciences Investors
N/A$467.37 million1,69875,645
N/A$466.83 million32,3764.18 million
N/A$450.31 million249,89223.94 million
Rigel Pharmaceuticals
N/A$446.33 million39,2072.37 million
Aldeyra Therapeutics
N/A$427.56 million12,8171.25 million
N/A$401.76 million7,9261.48 million
Innate Pharma
N/A$401.41 million629677,118Gap Up
N/A$391.34 million122106,098Gap Down
Shattuck Labs
N/A$390.79 million7,192213,785
N/A$390.07 million65,1833.93 million
N/A$375.73 million62282,365
Cabaletta Bio
N/A$356.98 million2,083139,501Analyst Report
News Coverage
N/A$335.01 million9,2901.37 million
Magenta Therapeutics
N/A$331.50 million1,919238,612
The How and Why of Investing in Biotech Stocks

One of the most fascinating and potentially risky sectors to invest in is the biotech sector. This is the sector that includes companies involved in the research and development of therapeutics and vaccines to relieve a myriad of conditions and diseases.

The Covid-19 pandemic brought on by the novel coronavirus in 2020 put the sector squarely in focus. However, due to the unprecedented assistance from the U.S. government through Operation Warp Speed (OWS) it was also an anomaly.

Seasoned investors in the biotech industry understand that products go through a lengthy, rigorous, and expensive testing process. However even when (and if) a drug makes it through that process, the product(s) still have to be approved by the U.S. Food & Drug Administration (FDA) before it can go to market.

And the harsh reality of the biotech sector is that many products will never make it to market, which adds a level of risk to any biotech investment. The good news is there are ways to help minimize the risk by understanding what qualities to look for in biotech stocks.


The biotech sector illustrates the risk-reward of investing in stocks more than almost any other sector. Biotech companies are involved in developing therapeutics and drugs for life-threatening conditions. Many of the companies in this sector are small-cap companies. Some are even penny stocks (meaning they have a stock price of under $5).

Biotech stocks are popular because, if these companies successfully bring a product to market, their stock price could double or more virtually overnight. On the other hand, perhaps no other sector comes with so much risk. The reality is that many of the products that these companies develop never make it out of clinical trials, or get approved by the FDA. And that means that investors can easily lose the majority of their investment.

In this article, we’ll describe what a biotech company is and how it is different from (and in some cases similar to) a pharmaceutical company. We’ll also share a few practical tips that can help you select a biotech stock.

How a Biotech Company Is Different From a Pharmaceutical Company?

The biotech and pharmaceutical sectors are related but more like cousins than siblings. One key point that distinguishes the two sectors is that investing in pharmaceutical companies are about what is and biotech stocks are about what could be. And that changes the risk profile for both.

A pharmaceutical company has revenue coming in from products that are commercially available and have other products in development. Because of this pharmaceutical companies are generally profitable and in some cases offer investors a dividend, which can be a significant part of an investor’s total return.

By contrast, a biotech company is primarily research-driven that are using science to develop a potential therapy or vaccine. Many of these companies are small-cap stocks that are not profitable. And even the small fraction of those that rarely pay a dividend.

Another distinction is that pharmaceutical companies spend a great deal of money in marketing and sales. On the other hand, biotech companies see their strength as being in research and development (R&D).

Where the two sectors overlap is that pharmaceutical companies are increasingly pulling back from research and are looking to partner with biotech firms for innovation. This helps create an opportunity for investors who know what to look for in a biotech stock.

How to Select a Biotech Stock

There’s no sure-fire way to take the risk out of biotech stocks. However, there are certain things you can look for to help manage your risk.

  1. Look for a “hot” area of biotech. This means looking for a company that is doing research for a disease or condition that affects a large segment of the population. However, as an investor, these are the companies that you should be looking for because there will be a high demand for the company’s products. The obvious reason is that the companies that were successful would be able to get a faster return on their significant R&D and licensing efforts.

    For example, during the Covid-19 pandemic companies that were developing vaccine candidates soared. However, investors can also look for biotech firms that are researching treatments for areas such as cancer, AIDS, heart disease and neurological conditions.

    Another reason to look for a hot area of research is that it can lead to breakthrough “orphan” drugs and treatments that – if they are first to market - are typically protected from competition for many years.

  2. Look at the company they keep. Many biotech companies are small-cap companies. This can help them maintain a singular focus. However biotech development is expensive and when smaller companies form collaborations with other companies, it can help provide financial and logistical support. And if one collaborator is good, more is better.

  3. As with many investment opportunities, cash is king. The record pace at which multiple Covid-19 vaccines were developed underscores the length of time it takes to bring a product to market. And that means that you should be looking for companies that have an ample cash reserve. It’s not uncommon for small-cap biotech firms to raise money through secondary share offerings. This can work. However, it comes at the expense of share dilution. Companies that continually need to issue share offerings should raise a caution flag for investors.

  4. It stands to reason that in addition to finding companies that have an ample supply of cash, you also want to find companies that are not overly extended with debt. Companies that are heavily burdened with debt will often need to raise more capital which can lead to an unsustainable spiral.

  5. Look for companies with a deep pipeline of products that are in clinical trials. Many biotech companies have one product candidate. However, that’s a high-risk, high-reward proposition for investors. If that product fails, a company might have no other way to recoup their R&D costs. But companies that have several products in development give themselves multiple bites at the apple.

  6. Just as investors want to look for a deep pipeline, they also want to see market-ready products. A deep pipeline is one thing, but at some point, a company has to be able to bring a product to market. Completing clinical trials on human patients is a good first start. However, that’s only the first step. The product needs approval by the U.S. Food & Drug Administration (FDA). And that can take some time. Nevertheless, getting a drug successfully through clinical trials is a good indicator that a product will come to market sooner rather than later.

  7. Look for biotech stocks that have the potential to rebound quickly. These are typically companies whose stocks are being sold on temporary bad news. The process of getting a drug to market is notoriously complex. Along the line, many speculative investors will trade on the news. However investors can use a temporary drop in share price as a great opportunity to buy on the dip. Of course, you have to believe that the news is actually much ado about nothing. If so, investors can use these opportunities to accumulate additional shares.

  8. Have trust for who is in charge. It’s important that the management team consists of not only business-savvy entrepreneurs but also individuals who have the necessary scientific or medical credentials. This ensures that the company will not only be able to allocate resources towards the most promising products, they will also be able to properly interpret research data and make corrections as necessary.

How to invest in biotech stocks?

The easiest and more popular way to invest in biotech stocks is to buy stocks of individual companies. However, investing in an exchange-traded funds (ETFs) can be a smart way to manage the inherent risk of this sector. There are several biotech ETFs that track an index (a basket) of biotech stocks. Some of the most popular biotech ETFs are:

  • S&P Biotech Select Industry Index (INDEXSP:SPSIBI)
  • NYSE Arca Biotechnology Index (INDEXNYSEGIS:BTK)
  • NASDAQ Biotechnology Index (INDEXNASDAQ:NBI)
  • iShares NASDAQ Biotechnology ETF (NASDAQ:IBB)

The final word on investing in biotech stocks

Investing in biotech stocks can be one of the most profitable sectors for risk-tolerant investors. Biotech companies are engaged in research and development for life-threatening conditions. If these companies are able to successfully bring a product to market, its stock price (which in some cases is trading as a penny stock) can double, triple or move even higher.

However, there’s also a tremendous risk to biotech stocks. The process to get a product approved is lengthy and expensive. And just getting a product through clinical trials is not sufficient. There is still an approval process through the FDA. And, unlike the speed at which Covid-19 vaccines have been approved, this can also be a lengthy process.

To invest in biotech stocks requires knowledge of not only financial fundamentals but also the science and medicine behind the company. Individual investors who have a background in science and medicine may have the ability to separate the contenders from the pretenders.



Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.